ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,996.66
      1.00%
      US Tech 100
      20,877.20
      1.72%
      Dow Jones
      43,487.83
      0.78%
      Brent Oil
      80.005
      0.00%
      Bitcoin
      104,786.33
      0.35%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. CervoMed Inc (CRVO) Quote

      CervoMed Inc

      CervoMed Inc (CRVO)

      NASDAQ
      2.11
      0.00
      (0.00%)
      Closed January 19 4:00PM
      Delayed by 15 minutes
      2.158
      0.048
      (2.27%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      2.158
      Bid
      2.07
      Ask
      6.00
      Volume
      69,280
      2.06 Day's Range 2.15
      1.80 52 Week Range 26.3789
      Market Cap
      17.812M
      Previous Close
      2.11
      Open
      2.12
      Last Trade
      50
      @
      2.12
      Last Trade Time
      Financial Volume
      $ 146,597
      VWAP
      2.116
      Average Volume (3m)
      453,003
      Shares Outstanding
      8,253,741
      Dividend Yield
      -
      PE Ratio
      -16.72
      Earnings Per Share (EPS)
      -0.26
      Revenue
      7.15M
      Net Profit
      -2.17M

      About CervoMed Inc

      Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.cervomed.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      CervoMed Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRVO. The last closing price for CervoMed was $2.11. Over the last year, CervoMed shares have traded in a share price range of $ 1.80 to $ 26.3789.

      CervoMed currently has 8,253,741 shares outstanding. The market capitalization of CervoMed is $17.42 million. CervoMed has a price to earnings ratio (PE ratio) of -16.72.

      Ask ADVFN Intelligence (AI)

      CRVO Latest News

      More News

      Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      January 13 2025
      Edgar (US Regulatory)

      CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today...

      December 12 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      December 10 2024
      Edgar (US Regulatory)

      CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

      —Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety...

      December 10 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      December 03 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 27 2024
      Edgar (US Regulatory)

      CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

      Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB...

      November 27 2024
      GlobeNewswire Inc.

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 14 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 13 2024
      Edgar (US Regulatory)

      CervoMed Announces Key Senior Leadership Appointments

      BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior...

      November 13 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.013-0.598802395212.1712.1711.98531337732.08772606CS
      4-0.0319-1.456687519982.18992.511.98532375252.2781154CS
      12-10.492-82.940711462512.6514.62151.84530033.75601952CS
      26-16.9843-88.726537563419.142320.631.82457935.81565477CS
      52-6.802-75.91517857148.9626.37891.81447007.62644704CS
      156-11.342-84.014814814813.526.37891.81137097.56417334CS
      260-11.342-84.014814814813.526.37891.81137097.56417334CS

      CRVO - Frequently Asked Questions (FAQ)

      What is the current CervoMed share price?
      The current share price of CervoMed is $ 2.158
      How many CervoMed shares are in issue?
      CervoMed has 8,253,741 shares in issue
      What is the market cap of CervoMed?
      The market capitalisation of CervoMed is USD 17.42M
      What is the 1 year trading range for CervoMed share price?
      CervoMed has traded in the range of $ 1.80 to $ 26.3789 during the past year
      What is the PE ratio of CervoMed?
      The price to earnings ratio of CervoMed is -16.72
      What is the cash to sales ratio of CervoMed?
      The cash to sales ratio of CervoMed is 5.08
      What is the reporting currency for CervoMed?
      CervoMed reports financial results in USD
      What is the latest annual turnover for CervoMed?
      The latest annual turnover of CervoMed is USD 7.15M
      What is the latest annual profit for CervoMed?
      The latest annual profit of CervoMed is USD -2.17M
      What is the registered address of CervoMed?
      The registered address for CervoMed is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the CervoMed website address?
      The website address for CervoMed is www.cervomed.com
      Which industry sector does CervoMed operate in?
      CervoMed operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BTCTBTC Digital Ltd
      $ 8.2697
      (73.73%)
      		61.45M
      BDMDBaird Medical Investment Holdings Ltd
      $ 8.80
      (62.36%)
      		18.63M
      CRKNCrown Electrokinetics Corporation
      $ 0.1235
      (54.96%)
      		764.86M
      NUKKNukkleus Inc
      $ 29.97
      (45.98%)
      		19.09M
      GSITGSI Technology
      $ 3.97
      (44.36%)
      		87.7M
      DOGZDogness International Corporation
      $ 18.23
      (-58.77%)
      		740.45k
      ORKTOrangeKloud Technology Inc
      $ 3.02
      (-24.88%)
      		21.08M
      PMAXPowell Max Ltd
      $ 0.6364
      (-23.31%)
      		4.17M
      LGCBLinkage Global Inc
      $ 0.2876
      (-22.27%)
      		890.66k
      YYAIConnexa Sports Technologies Inc
      $ 0.8299
      (-20.20%)
      		602.48k
      CRKNCrown Electrokinetics Corporation
      $ 0.1235
      (54.96%)
      		764.86M
      GCTKGlucoTrack Inc
      $ 0.0852
      (15.45%)
      		465.22M
      RIMEAlgorhythm Holdings Inc
      $ 0.0406
      (-4.02%)
      		387.23M
      TGLTreasure Global Inc
      $ 0.2459
      (14.75%)
      		267.1M
      NVDANVIDIA Corporation
      $ 137.71
      (3.10%)
      		201.4M

      CRVO Discussion

      View Posts
      tw0122 tw0122 2 weeks ago
      $2.20s some more data available Jan 2025 a few buy bites down here
      👍️0
      Covid19freak Covid19freak 2 months ago
      Phase 2b data of dementia trial imminent expected during this month , if positive this one going to 50 dollar and more
      👍️0
      JcOg323 JcOg323 2 months ago
      CRVO is about to pop this DEC!!!
      👍️0
      Monksdream Monksdream 4 months ago
      CRVO directionless
      👍️0

      Your Recent History

      NASDAQ
      CRVO
      CervoMed
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads